Highlights China Grand Pha.and Healthcare Hld. Ltd. Hong Kong S.E.

Equities

0512

BMG210A71198

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	04-29	MT
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	03-27	CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	03-25	MT
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	03-24	CI
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	03-19	CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	03-07	CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	02-08	MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	01-16	MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	12-27	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	12-27	CI
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	12-22	MT
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	12-13	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01	11-02	CI
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing	24/10/23	CI
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint	13/09/23	CI
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently	17/08/23	CI
Grand Pharmaceutical Group Limited Announces Phase III Study of Global Innovative Rdc Candidate Tlx591-Cdx Doses First Patient in China	14/08/23	CI
Grand Pharmaceutical's Profit Jumps in H1	11/08/23	MT
Grand Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	10/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights China Grand Pha.and Healthcare Hld. Ltd. Hong Kong S.E.

Equities

0512

BMG210A71198

Highlights

Filters